Oxytrol Switch For OAB Surfaces Questions On Delayed Diagnoses
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s application to switch the overactive bladder drug Oxytrol for Women must prove to FDA’s OTC advisors that women suffering urinary incontinence due to urinary tract infections, diabetes or other conditions appropriately can discontinue treatment and seek medical attention.